Increased Transglutaminase 2 Expression and Activity in Rodent Models of Obesity/Metabolic Syndrome and Aging
暂无分享,去创建一个
A. Leite-Moreira | B. Fanburg | I. Falcão-Pires | K. Penumatsa | R. Sutliff | S. Leite | Jing Ma | Chinmayee D. Bhedi | S. Nasirova
[1] B. Fanburg,et al. Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] K. Ha,et al. The vicious cycle between transglutaminase 2 and reactive oxygen species in hyperglycemic memory–induced endothelial dysfunction , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] W. Paulus,et al. Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction. , 2019, Circulation. Heart failure.
[4] J. Sowers,et al. Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor , 2019, Hypertension.
[5] G. Johnson,et al. Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension , 2019, American journal of hypertension.
[6] M. Gladwin,et al. Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction , 2018, The Journal of physiology.
[7] L. Santhanam,et al. Knockdown of transglutaminase-2 prevents early age-induced vascular changes in mice1. , 2018, Acta cirurgica brasileira.
[8] Soo-Youl Kim,et al. New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds , 2018, Medical Science.
[9] T. Finkel,et al. The role of mitochondria in aging , 2018, The Journal of clinical investigation.
[10] K. M. Choi,et al. Aging and anatomical variations in lung tissue stiffness. , 2018, American journal of physiology. Lung cellular and molecular physiology.
[11] E. Bedrick,et al. Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension. , 2018, The American journal of medicine.
[12] P. Camelliti,et al. Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor , 2018, Cell Death & Disease.
[13] Mario J. Garcia,et al. Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload. , 2018, Journal of molecular and cellular cardiology.
[14] M. Rojas,et al. Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics , 2018, Front. Med..
[15] B. Fanburg,et al. Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension. , 2017, American journal of physiology. Lung cellular and molecular physiology.
[16] Danica Chen,et al. The Intersection of Aging Biology and the Pathobiology of Lung Diseases: A Joint NHLBI/NIA Workshop. , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.
[17] R. Mrowka. Arterial hypertension , 2017, Acta physiologica.
[18] A. Choi,et al. Glucose Transporter 1‐Dependent Glycolysis Is Increased during Aging‐Related Lung Fibrosis, and Phloretin Inhibits Lung Fibrosis , 2017, American journal of respiratory cell and molecular biology.
[19] C. Greenberg,et al. Role of tissue transglutaminase-2 (TG2)-mediated aminylation in biological processes , 2017, Amino Acids.
[20] A. Oberg,et al. Cellular senescence mediates fibrotic pulmonary disease , 2017, Nature Communications.
[21] M. Halushka,et al. Tissue Transglutaminase Modulates Vascular Stiffness and Function Through Crosslinking‐Dependent and Crosslinking‐Independent Functions , 2017, Journal of the American Heart Association.
[22] B. Levine,et al. Role of tissue transglutaminase in age-associated ventricular stiffness , 2016, Amino Acids.
[23] D. Grinnan,et al. The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension , 2016, Journal of diabetes research.
[24] F. Paneni,et al. Ageing, metabolism and cardiovascular disease , 2016, The Journal of physiology.
[25] W. Paulus,et al. Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome , 2016, Circulation. Heart failure.
[26] Zhaoyang Feng,et al. Reprogramming of energy metabolism as a driver of aging , 2016, Oncotarget.
[27] T. Gillebert,et al. Afterload-induced diastolic dysfunction contributes to high filling pressures in experimental heart failure with preserved ejection fraction. , 2015, American journal of physiology. Heart and circulatory physiology.
[28] A. Leite-Moreira,et al. Echocardiography and invasive hemodynamics during stress testing for diagnosis of heart failure with preserved ejection fraction: an experimental study. , 2015, American journal of physiology. Heart and circulatory physiology.
[29] R. Mohney,et al. Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease. , 2015, Journal of proteome research.
[30] N. Muma,et al. Serotonylation and Transamidation of Other Monoamines. , 2015, ACS chemical neuroscience.
[31] J. Harral,et al. Obesity-Related Pulmonary Arterial Hypertension in Rats Correlates with Increased Circulating Inflammatory Cytokines and Lipids and with Oxidant Damage in the Arterial Wall but not with Hypoxia , 2014, Pulmonary circulation.
[32] S. Comhair,et al. Role of hypoxia-induced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation. , 2014, American journal of physiology. Lung cellular and molecular physiology.
[33] N. Frangogiannis,et al. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. , 2014, Translational research : the journal of laboratory and clinical medicine.
[34] Richard T. Lee,et al. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. , 2014, Circulation research.
[35] Thomas H Thatcher,et al. Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules. , 2014, American journal of respiratory cell and molecular biology.
[36] M. Halushka,et al. Exercise, Vascular Stiffness, and Tissue Transglutaminase , 2014, Journal of the American Heart Association.
[37] K. Penumatsa,et al. Transglutaminase 2-mediated serotonylation in pulmonary hypertension. , 2014, American journal of physiology. Lung cellular and molecular physiology.
[38] B. Fanburg,et al. Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice. , 2014, ACS chemical biology.
[39] M. Kieliszek,et al. Microbial transglutaminase and its application in the food industry. A review , 2013, Folia Microbiologica.
[40] W. Paulus,et al. Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model , 2013, Circulation. Heart failure.
[41] K. Mehta,et al. Tissue Transglutaminase Constitutively Activates HIF-1α Promoter and Nuclear Factor-κB via a Non-Canonical Pathway , 2012, PloS one.
[42] James Strait,et al. Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease , 2012, Heart Failure Reviews.
[43] M. Sekiguchi,et al. Age-dependent increases in the oxidative damage of DNA, RNA, and their metabolites in normal and senescence-accelerated mice analyzed by LC-MS/MS: urinary 8-oxoguanosine as a novel biomarker of aging. , 2012, Free radical biology & medicine.
[44] E. Goldsmith,et al. Diabetes-Induced Alterations in the Extracellular Matrix and Their Impact on Myocardial Function , 2012, Microscopy and Microanalysis.
[45] Pruthvi N. Shetty,et al. Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function , 2011, Journal of cardiovascular disease research.
[46] D. Sorescu,et al. Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. , 2011, American journal of physiology. Heart and circulatory physiology.
[47] G. Escames,et al. Effect of a combined treatment with growth hormone and melatonin in the cardiological aging on male SAMP8 mice. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.
[48] Yingling Liu,et al. Role of protein transamidation in serotonin-induced proliferation and migration of pulmonary artery smooth muscle cells. , 2011, American journal of respiratory cell and molecular biology.
[49] N. Frangogiannis,et al. Aging and Cardiac Fibrosis. , 2011, Aging and disease.
[50] T. Ørntoft,et al. Pressure Load: The Main Factor for Altered Gene Expression in Right Ventricular Hypertrophy in Chronic Hypoxic Rats , 2011, PloS one.
[51] J. Juliard. [Heart failure in the elderly]. , 2009, La Revue du praticien.
[52] Michael Bader,et al. Intracellular Serotonin Modulates Insulin Secretion from Pancreatic β-Cells by Protein Serotonylation , 2009, PLoS biology.
[53] S. Twigg,et al. Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers , 2008, Vascular health and risk management.
[54] M. Picken,et al. Dynamic blood pressure load and nephropathy in the ZSF1 (fa/fa cp) model of type 2 diabetes. , 2007, American journal of physiology. Renal physiology.
[55] Adrian Pistea,et al. Flow-Dependent Remodeling of Small Arteries in Mice Deficient for Tissue-Type Transglutaminase: Possible Compensation by Macrophage-Derived Factor XIII , 2006, Circulation research.
[56] L. Ferrucci,et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.
[57] F. Villarreal,et al. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. , 2006, Journal of the American College of Cardiology.
[58] Michael C. Wendl,et al. Argonaute—a database for gene regulation by mammalian microRNAs , 2005, BMC Bioinformatics.
[59] Linghong Huang,et al. Inhibition of Transglutaminase Activity Reduces Extracellular Matrix Accumulation Induced by High Glucose Levels in Proximal Tubular Epithelial Cells* , 2004, Journal of Biological Chemistry.
[60] D. Kass,et al. What Mechanisms Underlie Diastolic Dysfunction in Heart Failure? , 2004, Circulation research.
[61] D. Vorp,et al. Crosslinking of collagen gels by transglutaminase. , 2004, Journal of biomedical materials research. Part A.
[62] J. Piccini,et al. New insights into diastolic heart failure: role of diabetes mellitus. , 2004, The American journal of medicine.
[63] Rita Casadio,et al. Transglutaminases: nature's biological glues. , 2002, The Biochemical journal.
[64] M. Cooper,et al. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.
[65] G. Dorn,et al. Cardiac Specific Overexpression of Transglutaminase II (Gh) Results in a Unique Hypertrophy Phenotype Independent of Phospholipase C Activation* , 1999, The Journal of Biological Chemistry.
[66] T. Kurokawa,et al. Difference between senescence-accelerated prone and resistant mice in response to insulin in the heart , 1998, Mechanisms of Ageing and Development.
[67] K. Kashima,et al. Immunohistochemical study on tissue transglutaminase and copper-zinc superoxide dismutase in human myocardium: Its relevance to apoptosis detected by the nick end labelling method , 1997, Virchows Archiv.
[68] R. Rice,et al. Transglutaminases: multifunctional cross‐linking enzymes that stabilize tissues , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[69] P. Blanchette,et al. Diastolic dysfunction in elderly patients with congestive heart failure. , 1989, The American journal of cardiology.
[70] D. Mosher,et al. Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa. , 1979, The Journal of clinical investigation.
[71] K. Brown. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype , 2012, Breast Cancer Research and Treatment.
[72] Edward G Lakatta,et al. Aging-associated cardiovascular changes and their relationship to heart failure. , 2012, Heart failure clinics.